Satyaki Sarkar

Satyaki Sarkar

Auto-generated profile, based on publicly available information

Satyaki Sarkar

Department of Anesthesiology and Critical Care AIIMS Bhubaneswar India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Phytomedicine
Verified
Journal Article
Closed access
SGShanky Garg
Shanky Garg
RMRajiv Kumar Malhotra
Rajiv Kumar Malhotra
SKSana Irfan Khan
Sana Irfan Khan
SSSatyaki Sarkar
Satyaki Sarkar
PSPn Susrutha
Pn Susrutha
DADharamveer Singh Arya
Dharamveer Singh Arya


10 April 2023 in Heliyon
Verified
Journal Article
Open access
JMJayanta Kumar Mitra
Jayanta Kumar Mitra
UHUpendra Hansda
Upendra Hansda
DBDebapriya Bandyopadhyay
Debapriya Bandyopadhyay
SSSatyaki Sarkar
Satyaki Sarkar
JSJoshna Sahoo
Joshna Sahoo
Mortality in acute organophosphate (OP) poisoning remains high despite current standard therapy with atropine and oximes. Due to dose-limiting side effects of atropine, novel therapies are targeting other putative mechanisms of injury, including oxidative damage, to reduce atropine dosage. N-acetylcysteine (NAC) and magnesium sulfate (MgSO4) have different mechanisms of actions and should act synergistically in OP poisoning. In this study, we wanted to evaluate whether this novel combination, used as an adjuvant to standard care, could improve clinical outcomes. The study was conducted in the Emergency Department and ICU of AIIMS Bhubaneswar (a tertiary care center and government teaching institute) between July 2019 and July 2021. Eighty-eight adult patients with history and clinical features of acute OP poisoning were randomly allocated (1:1) into two groups. The Study group received 600 mg NAC via nasogastric tube thrice daily for 3 days plus a single dose of 4 g Inj. MgSO4 IV on first day and the Control group received suitably matched placebo (double-blinding) – in addition to standard care in both the groups. The primary outcome measure was to compare the total dose of Inj. Atropine required (cumulative over the entire treatment duration) between the control group and the study group receiving NAC and MgSO4. The secondary outcome measures were lengths of ICU and hospital stays, need and duration of mechanical ventilation, the differences in BuChE activity, oxidative stress biomarkers – MDA and GSH levels, the incidences of adverse effects including delayed sequalae like intermediate syndrome and OPIDN, and comparison of mortality between the two groups. Data from 43 patients in Control and 42 patients in Study group was finally analyzed. The baseline parameters were comparable. Total atropine requirements were lower in the Study group [175.33 ± 81.25 mg (150.01–200.65)] compared to the Control [210.63 ± 102.29 mg (179.15–242.11)] [Mean ± SD (95% CI)], but was not statistically significant. No significant differences in any of the other clinical or biochemical parameters were noted. The N-acetylcysteine and MgSO4 combination as adjuvants failed to significantly reduce atropine requirements, ICU/hospital stay, mechanical ventilatory requirements, mortality and did not offer protection against oxidative damage.

1 June 2021 in Korean Journal of Anesthesiology
Verified
Journal Article
Open access
PDF file
CMChitta Ranjan Mohanty
Chitta Ranjan Mohanty
SBSnigdha Bellapukonda
Snigdha Bellapukonda
NTNitish Topono
Nitish Topono
SSSatyaki Sarkar
Satyaki Sarkar
PTPriyank Tapuria
Priyank Tapuria

25 May 2026 in Pediatric Anesthesia
Verified
Journal Article
Closed access
SSSatyaki Sarkar
Satyaki Sarkar
NMNitasha Mishra
Nitasha Mishra
PRParnandi Bhaskar Rao
Parnandi Bhaskar Rao
PTPriyank Tapuria
Priyank Tapuria